Jula Inrig - 31 Jan 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role: Chief Medical Officer
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol: TVTX
Transactions as of: 31 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2022, 15:20:53 UTC
Previous filing: 04 Jan 2022
Next filing: 06 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TVTX	Performance-based restricted stock units	Award	$0	+8,000		$0.000000	8,000	31 Jan 2022	Common Stock	8,000		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2	This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

Content

Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.